BioNet https://validator.w3.org/feed/docs/rss2.html Rapid Biomimetic Nanovaccine for Personalized Cancer Therapy Hybrid Nanocarriers Could Enable Targeted Vaccine Delivery in the Lungs Avidity of pertussis toxin antibodies following vaccination with genetically versus chemically detoxified pertussis toxin-containing vaccines during pregnancy The European Commission Grants Marketing Authorisation for a First-of-its-Kind Pertussis-Only Vaccine for Vaccination of Teenagers, Adults and Pregnant Women in the European Union New Pertussis Vaccine Set for Implementation The golden age of vaccine development BioNet Achieves EU-GMP Certification for its Pertussis Vaccine Manufacturing BioNet Receives Positive CHMP Opinion from EMA for VacPertagen, a Recombinant Vaccine Against Pertussis Careers Maintenance Technician 2 Clinical Study on Reduced-Dose Pertussis Vaccine in Thailand MIT researchers develop AI tool to improve flu vaccine strain selection How AI could speed the development of RNA vaccines and other RNA therapies Tweak to mRNA Vaccine “Recipe” Improves Safety and Efficacy 50 Years of Vaccines: How EPI Saved 154M Lives Globally Contact us Admin Staff 1-Driver Running with Heart, Driven by Values The future of child health: Innovations expanding access to immunization Quality Assurance Staff 3-Operational Quality & Batch Release Quality Control Staff 3-Biology Laboratory Meet BioNet at APS-MCV 2025 | Advancing Pertussis Protection Together New mRNA vaccine is more effective and less costly to develop, study finds Partnerships Pertussis Immunity 5 Years After Booster Vaccination With Recombinant Pertussis Vaccines News center Home Transplacental transfer of maternal antibodies following immunization with recombinant pertussis vaccines during pregnancy: Real-world evidence Production Staff 3-Primary Manufacturing (Support) Machine Learning in Immunology: From Epitope Prediction to Smarter Vaccine Design Project Engineer-IT Effective and safe transfer of maternal antibodies persisting two months postpartum following maternal immunization with different doses of recombinant pertussis-containing vaccines B cell discovery could supercharge future vaccine development Antibody persistence 2 and 3 years after booster vaccination of adolescents with recombinant acellular pertussis monovalent aPgen or combined TdaPgen vaccines A phase 2 randomized controlled dose-ranging trial of recombinant pertussis booster vaccines containing genetically inactivated pertussis toxin in women of childbearing age BioNet x Isaanbags: A CSR Story of Craft and Care UMich study shows how generative AI could use personality to combat vaccine myths A reduced-dose recombinant pertussis vaccine booster in Thai adolescents: a phase 2/3, observer-blinded, randomised controlled, non-inferiority trial Blood Test Predicts How Long Vaccines Will Protect You Cancer vaccines have stumbled, but the approach is gaining new steam Infant Responses to Primary Immunization Following Vaccination in Pregnancy With Varying Doses of Recombinant Acellular Pertussis Vaccine Alone or Combined With Tetanus-Diphtheria Production Staff 2-Secondary Manufacturing (Packing) Enhanced post-licensure safety surveillance of a new recombinant acellular pertussis vaccine licensed as a monovalent (aP, Pertagen®) and tetanus, reduced-dose diphtheria combination (TdaP, Boostagen®) vaccine for immunization of adolescents and adults in Thailand Nanoparticle Plus mRNA Attacks Pancreatic Liver Metastases in Mice New Research Boosts Future Whooping Cough Vaccines Groundbreaking advances in tuberculosis vaccine development and therapies BioNet Wins BARDA Patch Forward Prize for Microneedle mRNA Vaccine Innovation BioNet and Bio Farma Sign Strategic MoU to Expand TdaP Vaccine Access in ASEAN Discovery could eliminate need to refrigerate vaccines and protein-based drugs Company